Haisco Pharmaceutical Group (002653.SZ): Obtained acceptance of the IND application for innovative drug injection HSK55718.

Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Shanghai Haisinuo Pharmaceutical Technology Co., Ltd., recently received a "Notice of Acceptance" issued by the National Medical Products Administration for the drug "HSK55718". HSK55718 is a small molecule non-opioid innovative analgesic developed by the company with independent intellectual property rights. It is expected to provide a safer and more effective analgesic option for patients with acute pain by reducing adverse reactions and avoiding the risk of addiction while meeting the pain control needs of patients. According to the announcement on the classification and application requirements for the registration of chemical drugs issued by the National Medical Products Administration (No. 44 of 2020), this drug belongs to Class 1 of chemical drugs.